Stocks Health care APYX
NASDAQ · Health careApyx Medical Corp (APYX)
Apyx Medical Corp brought in $59.6M of revenue over the twelve months to September 30, 2026, up 24.4% from a year earlier. It posted a net loss of $8.4M. In fiscal 2025 capital spending exceeded operating cash flow by $9.1M. At September 30, 2026 it held $25.8M in cash against $37.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Apyx Medical Corp
- Net worth
- Apyx Medical Corp has a market value (market cap) of $123.8M at the latest share price, and shareholders' equity of $9.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $52.8M (+9.9% year on year), with a net loss of $11.2M. Over the 12 months to September 30, 2026: revenue $59.6M, net loss $8.4M.
- Cash flow
- In fiscal 2025 operations used $8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Apyx Medical Corp's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Apyx Medical Corp does
Apyx Medical Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker APYX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $52.8M | -$11.2M | -$0.27 | -$9.1M |
| 2024 | $48.1M | -$23.5M | -$0.66 | -$18.8M |
| 2023 | $52.3M | -$18.7M | -$0.54 | -$5.8M |
| 2022 | $44.5M | -$23.2M | -$0.67 | -$21.3M |
| 2021 | $48.5M | -$15.2M | -$0.44 | -$11.2M |
| 2020 | $27.7M | -$11.9M | -$0.35 | -$16.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where APYX ranks in Health care
Latest SEC filings
What Apyx Medical Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 9% to $14M versus the same quarter last year; diluted EPS -$0.04 versus -$0.05.
- November 5, 2026
- October 28, 2026Passive stake (5% or more) SCHEDULE 13G
- September 29, 2026Other event 8-K
- August 7, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 22% to $13.9M versus the same quarter last year; diluted EPS -$0.07 versus -$0.09.
- August 6, 2026
- July 24, 2026Other event 8-K
- July 21, 2026Passive stake changed SCHEDULE 13G/A
- June 26, 2026Proxy statement DEF 14A
Insider trades
What the people running Apyx Medical Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Waldman LawrenceDirector | Exercised optionsindirect | 12,000 | $22.6K |
| June 30, 2026 | Waldman LawrenceDirector | Shares withheld for taxindirect | 5,024 | $22.6K |
| June 15, 2026 | Roman Shawn DavidChief Operating Officer | Exercised optionsindirect | 15,000 | $48.5K |
| June 15, 2026 | Roman Shawn DavidChief Operating Officer | Shares withheld for taxindirect | 10,533 | $48.5K |
| June 11, 2026 | Vizirgianakis Stavros G.Director | Received as pay | 450,000 | - |
| March 15, 2026 | Citronowicz MosheSenior Vice President | Exercised options | 37,000 | $66.6K |
| January 27, 2026 | Roman Shawn DavidChief Operating Officer | Exercised optionsindirect | 12,000 | $21.6K |
Who owns APYX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.99% | February 13, 2026 |
| Royce & Associates LP13G, passive | 7.81% | July 21, 2026 |
| Kanen Wealth Management LLC13G, passive with 3 related filers | 5.4% | October 28, 2026 |
| Stavros G. Vizirgianakis13D, may seek influence | 5.04% | May 9, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 68 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 6,540,496 | +3,100,192 |
| Royce & Associates LP | 3,274,064 | +662,840 |
| Archon Capital Management LLC | 2,644,717 | -146,206 |
| Vanguard Capital Management LLC | 1,534,847 | -20,425 |
| Essex Investment Management Co LLC | 1,136,630 | +235,232 |
| AIGH Capital Management LLC | 1,128,343 | +23,373 |
| Silverberg Bernstein Capital Management LLC | 1,039,641 | -1,429 |
| Commonwealth Equity Services, LLC | 649,061 | 0 |
| Horizon Kinetics Asset Management LLC | 585,000 | -30,000 |
| BlackRock, Inc. | 560,986 | +33,238 |
| Renaissance Technologies LLC | 554,278 | +251,883 |
| Taylor Frigon Capital Management LLC | 413,602 | -957 |
| Geode Capital Management, LLC | 400,600 | +9,244 |
| Legato Capital Management LLC | 382,762 | +101,873 |
| Sei Investments Co | 281,029 | -317,226 |
| Huntleigh Advisors, Inc. | 263,231 | +17,311 |
| Millennium Management LLC | 242,663 | -19,395 |
| Marshall Wace, Llp | 236,466 | +174,630 |
| Vanguard Fiduciary Trust Co | 224,021 | +21,340 |
| Susquehanna International Group, Llp | 216,263 | -51,298 |
Insiders
4 insiders reported holding 2,718,476 shares in total, about $8M at the last price.
| Holder | Shares |
|---|---|
| Vizirgianakis Stavros G.Director | 2,196,191 |
| Citronowicz MosheSenior Vice President | 493,504 |
| Roman Shawn DavidChief Operating Officer | 16,46716,467 held indirectly |
| Waldman LawrenceDirector | 12,31412,314 held indirectly |
Questions about APYX
What does Apyx Medical Corp do?
Apyx Medical Corp is a company in the Health care sector, listed on NASDAQ as APYX. Its shares trade on NASDAQ under the ticker APYX.
What is Apyx Medical Corp's net worth?
Apyx Medical Corp has a market value (market cap) of $123.8M at the latest share price, and shareholders' equity of $9.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Apyx Medical Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $8.4M on revenue of $59.6M.
How much revenue does Apyx Medical Corp make?
Over the twelve months to September 30, 2026 Apyx Medical Corp reported revenue of $59.6M. That is 24.4% more than a year earlier.
When did Apyx Medical Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Apyx Medical Corp's next earnings report?
Apyx Medical Corp's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare APYX with
Follow APYX
Get an email when Apyx Medical Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Apyx Medical Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.